WASHINGTON (AP) -- Federal health regulators say they have halted Amgen's studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial.
The Food and Drug Administration says it is gathering information about the death, but has shut down all studies of the drug in children.
Sensipar is approved for adults to treat over-activity of the parathyroid gland. Amgen Inc. had been studying the drug to see whether it works in children.
The FDA says in a statement it is unclear whether Amgen's drug had a role in the patient's death, but it is reminding doctors to prescribe it carefully.
The agency says doctors should monitor patients' calcium levels to make sure they don't fall to dangerous levels.
Copyright 2013 Scripps Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
One person will win a three-year lease on a 2013 Honda Civic Lx Sedan automatic.
Click to see the latest mugshots, plus this week's wanted fugitives.
This feature packed upgrade brings you faster performance, easier navigation, and stunning improvements to photos, video and readability.
Latest News Stories
Authorities won't say specifically why, but they think a letter purported to be from a New Hampshire teenager missing for nearly two months might in fact be the real thing. Abigail Hernandez was last seen on October 9.